MOUNTAIN VIEW, Calif., Jan. 28 /PRNewswire/ -- Clontech Laboratories,
Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the
imminent (February 20, 2008) release of its ProteoTuner systems, which will
be featured in the April issue of Clontechniques, the company's quarterly
newsletter. Based on work by researchers at Stanford University and
licensed from Stanford, the ProteoTuner systems use a unique technology to
regulate the amount of protein of interest present in a cell, quickly and
directly. This new technique enables direct manipulation of the in vivo
level of a specific protein of interest, making it a powerful tool for
analyzing protein function. Because the system has very low toxicity, it is
also suitable for animal studies.
"As a long-standing leader in the field of gene expression control,
Clontech is proud to add the ProteoTuner systems to its extensive
collection of gene and protein control systems, which include the Tet-On(R)
Advanced and Tet-Off(R) Advanced Inducible Gene Expression systems for gene
expression control and the Knockout(TM) RNAi systems for mRNA knockdown.
Each of these three systems has particular, complementary strengths: the
tight regulation of the Tet systems, Knockout RNAi's excellent control of
endogenous protein levels, and the fast control of protein levels via the
ProteoTuner systems. Each can be used independently or combined to enable
exquisite control over protein expression," said Carol Lou, General Manager
of Clontech Laboratories, Inc.
Clontech's ProteoTuner systems have broad applications in basic and
applied research. The fast kinetics of protein
stabilization/destabilization make it possible to study transient effects
of the protein of interest that might otherwise have been masked. The
ability to directly control the level of functional protein also makes this
technology an unprecedented tool for dissecting the roles of
multifunctional proteins, by directly and specifically "tuning" the level
of a protein of interest in the cell. Thus, the ProteoTuner systems offer a
unique new resource: the ability to directly regulate protein levels
without affecting the normal translational and transcriptional activities
of the gene of interest.
About Clontech Laboratories, Inc.
Clontech Laboratories, Inc. develops, produces, and markets
leading-edge biological products to the life science market worldwide.
Clontech has approximately 2,000 products that enable life science
researchers to study genes, their products, and their cellular function
through the use of innovative and powerful tools for gene cloning,
labeling, and expression; as well as for elucidating protein:protein
interactions; isolating and purifying DNA and proteins; and conducting a
wide variety of PCR experiments. Clontech is a wholly-owned subsidiary of
Takara Bio Inc. For more information visit http://www.clontech.com
About Takara Bio Inc.
Takara Bio Inc. is an innovative biotechnology company based in Shiga,
Japan. As a world leader in biotechnology research and development, Takara
Bio was the first company to market PCR technology in Japan and is also the
developer of the RetroNectin(R) reagent, which is a world-standard in gene
therapy protocols. In addition to providing research reagents and equipment
to the life science research market, Takara Bio has active research and
product development activities in the fields of gene and cell-based
therapy, and agricultural biotechnology; and is committed to preventing
disease and improving the quality of life for all people through the use of
biotechnology. Through strategic alliances with other industry leaders, the
Company aims to extend its reach around the world. More information is
available at http://www.takara-bio.com
SOURCE Clontech Laboratories, Inc.